(Elsevier) Ten percent of patients with prostate cancer develop locally invasive and metastatic disease, which increases the severity of the disease and likelihood of death and limits treatment options. A report in The American Journal of Pathology indicates that a significantly lower presence of syntaphilin (SNPH) -- a mitochondrial protein -- within the tumor's central core versus at the tumor's invasive outer edge, may identify patients at increased risk of metastasis. These patients may require more rigorous testing, surveillance, and treatment.